Evidence map›Paper›PMID 31483918›Full record

ArticleCancer science2019

Tyrosine kinase Eph receptor A6 sensitizes glioma-initiating cells towards bone morphogenetic protein-induced apoptosis.

Erna Raja, Masato Morikawa, Jun Nishida, Ryo Tanabe, Kei Takahashi, Howard J Seeherman, Nobuhito Saito, Tomoki Todo, Kohei Miyazono

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. The TGF-β Family in Glioblastoma.International journal of molecular sciences · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Erna RajaDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masato MorikawaDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6191-7176
Jun NishidaDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5098-9361
Ryo TanabeDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kei TakahashiDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Howard J SeehermanBioventus LLC, Boston, MA, USA.
Nobuhito SaitoDepartment of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tomoki TodoDivision of Innovative Cancer Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kohei MiyazonoDepartment of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0001-7341-0172
The University of Tokyo · JPBioVentures (United States) · USThe Cancer Institute Hospital · JP

Funding

Japan Society for the Promotion of Science (JSPS)KAKENHIMinistry of Education, Culture, Sports, Science, and Technology of Japan (MEXT)
6 · The paper itself

Abstract

Bone morphogenetic protein (BMP) signaling plays important roles in glioblastoma multiforme (GBM), a lethal form of brain tumor. BMP reduces GBM tumorigenicity through its differentiation- and apoptosis-inducing effects on glioma-initiating cells (GIC). However, some GIC do not respond to the tumor suppressive effects of BMP. Using a phosphoreceptor tyrosine kinase array, we found that EPHA6 (erythropoietin-producing hepatocellular carcinoma receptor A6) phosphorylation was regulated by BMP-2 signaling in some GIC. Analysis of The Cancer Genome Atlas showed that EPHA6 expression was lower in patients with GBM than in the normal brain, and that high EPHA6 expression was correlated with better prognosis. EPHA6 receptor increased the susceptibility of both sensitive and resistant GIC to BMP-2-induced apoptosis. The cooperative effect on apoptosis induction depended on the kinase activity of BMP type I receptor but was independent of EPHA6 kinase function. Overexpression of the EPHA6 receptor in GIC resulted in the formation of a protein complex of EPHA6 receptor and the BMP type I receptor ALK-2, which was associated with BMP-induced apoptosis in GIC. Intracranial injection of GIC into nude mice showed that gain-of-function of EPHA6 together with BMP-2 pretreatment slowed GBM tumor progression in the mouse brain and promoted mouse survival. In summary, EPHA6 together with BMP-2 signaling led to apoptotic cell death in GIC, and thus is a putative tumor suppressor in GBM.

Indexed as

ApoptosisActivin Receptors, Type IAnimalsBone Morphogenetic Protein 2Bone Morphogenetic Protein Receptors, Type IBone Morphogenetic ProteinsBrainBrain NeoplasmsCell Line, TumorDisease ProgressionGlioblastomaGliomaHumansMiceMice, NudeNeoplasm TransplantationActivin Receptors, Type IACVR1 protein, humanBone Morphogenetic Protein 2Bone Morphogenetic Protein Receptors, Type IBone Morphogenetic ProteinsReceptor, EphA6Tumor Suppressor Proteinsapoptosisbone morphogenetic protein-2cancer stem cellEPHA6glioblastoma

Identifiers

PMID31483918
PMCPMC6825014
OpenAlexW2972002605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.